

## **Uttar Pradesh's Pharma Sector Gains Momentum as Industry Leaders Express Strong Investment Interest**

**- Pharma Ready Ecosystem: UP Expands Lalitpur Park to Over 1,400 Acres and Medical Device & Formulation Parks Near Noida Airport to 600 Acres**

**-From Infrastructure to Innovation: Pharma Conclave 1.0 Positions UP as India's Next Pharma Growth Hub**

**Lucknow, February 5:** The Government of Uttar Pradesh successfully organized Pharma Conclave 1.0 in Lucknow, bringing together leading pharmaceutical companies, industry associations, policymakers, regulators, research institutions, and investors to chart the State's pharma growth roadmap. Inaugurated by Hon'ble Chief Minister Shri Yogi Adityanath along with senior ministers and industry leaders, the conclave highlighted Uttar Pradesh's emergence as a business-friendly and investment-ready hub for pharmaceutical manufacturing and healthcare innovation—driven by strong governance, improved law and order, and progressive policy support.

Acting on the suggestions received during the conclave under the guidance of the Hon'ble Chief Minister—who emphasized that bulk drug manufacturing units of the red and orange categories should utilize land in Lalitpur in addition to Noida—the State is accelerating the development of a future-ready pharma ecosystem through UPSIDA's Lalitpur Pharma Park. Phase I spans 352.91 acres, dedicated to formulation units, bulk drugs, and common infrastructure, while Phase II, covering 1,465 acres, is under development, for which an Expression of Interest (EOI) has been floated. Backed by an overall land bank of nearly 8,000 acres, Uttar Pradesh is strategically positioning itself as a leading destination for pharma investments.

Strengthening this ecosystem further, the Yamuna Expressway Industrial Development Authority is developing a 350-acre Medical Device Park in Sector-28, equipped with advanced testing laboratories and an ASCA certification facility to reduce dependence on overseas testing. Additionally, a 250-acre Pharma Formulation Park is planned in Sector-7 near the Noida International Airport, reinforcing Uttar Pradesh's potential to emerge as North India's key healthcare manufacturing hub with strong export connectivity.

A major highlight of Pharma Conclave 1.0 was the announcement of an investment intent of nearly ₹10,000 crore, along with the exchange of 11 Memorandums of Understanding (MoUs) in pharmaceuticals and medical devices. These proposals are expected to significantly enhance manufacturing capacity, generate employment, and strengthen healthcare supply chains—accelerating the overall growth of the State's pharma sector.

### **Research, Talent & Innovation Support**

Pharma Conclave 1.0 strongly underscored the importance of building a resilient research and innovation backbone. Leading scientists and institutional representatives—including Dr. Radha Rangarajan (CDRI), Prof. Shubhini A. Saraf (NIPER Raebareli), Dr. Neelima Mishra (National Institute of Biologicals), and Dr. Seema Pai (ISCR)—shared valuable insights on strengthening scientific capabilities in the State.

The conclave saw strong participation from leading pharma companies, highlighting interest in expanding operations in Uttar Pradesh. Stakeholders discussed growth, investments, and partnerships, reaffirming the State as a preferred destination. Infrastructure emerged as key, with leaders stressing plug-and-play facilities, ready land, and compliance-ready spaces to fast-track projects and boost competitiveness.

### **Policy Support & Regulatory Ease**

The conclave also highlighted the critical role of policy support and regulatory facilitation in shaping the State’s pharma growth trajectory. Key industry associations—including Shri Namit Joshi (Pharmexcil), Shri Sudarshan Jain (IPA), Dr. Viranchi Shah (IDMA), Shri A. P. Rameshwar Rao (BDMAI), Shri Anil Matai (OPPI) and Smt. Mamta Sharma (CII)—emphasized regulatory simplification, faster approvals, export facilitation, and innovation financing.

They noted that cluster-based manufacturing ecosystems and stable policy frameworks would be pivotal in attracting multinational investments, reflecting strong industry confidence in Uttar Pradesh’s progressive industrial environment.

### **Industry Insights**

Industry leaders including Shri MSN Reddy (MSN Laboratories), Shri Aditya Burman (Dabur India Ltd.), and Shri A. V. P. S. Chakravarti (FOPE – T&A) shared perspectives on investment expansion, contract manufacturing opportunities, and the growing global demand for botanical and traditional medicine products. Shri Aditya Burman highlighted the importance of certification frameworks and evidence-based research in biopharma and AYUSH.

Pharma Conclave 1.0 reflects Uttar Pradesh’s strong regulatory commitment and industry partnership. With rising investments, a focus on innovation, and robust compliance ecosystems, the State is building a future-ready pharma landscape. The FSDA is also acting as a proactive facilitator to support investments while ensuring quality, safety, and ease of doing business,” said Dr. Roshan Jacob, Secretary, Food Safety & Drug Administration.

-----